Literature DB >> 22782458

4-aminopyridine toxicity: a case report and review of the literature.

Andrew M King1, Nathan B Menke, Kenneth D Katz, Anthony F Pizon.   

Abstract

INTRODUCTION: 4-Aminopyridine (4-AP) selectively blocks voltage-gated potassium channels, prolongs the action potential, increases calcium influx, and subsequently, enhances interneuronal and neuromuscular synaptic transmission. This medication has been studied and used in many disease processes hallmarked by poor neuronal transmission in both the central and peripheral nervous systems including: multiple sclerosis (MS), spinal cord injuries (SCI), botulism, Lambert-Eaton syndrome, and myasthenia gravis. It has also been postulated as a potential treatment of verapamil toxicity and reversal agent for anesthesia-induced neuromuscular blockade. To date, there have been limited reports of either intentional or accidental 4-AP toxicity in humans. Both a case of a patient with 4-AP toxicity and review of the literature are discussed, highlighting commonalities observed in overdose. CASE REPORT: A 37-year-old man with progressive MS presented with diaphoresis, delirium, agitation, and choreathetoid movements after a presumed 4-AP overdose. 4-AP concentration at 6 h was 140 ng/mL. With aggressive benzodiazepine administration and intubation, he recovered uneventfully. DISCUSSION: The commonalities associated with 4-AP toxicity conforms to what is known about its mechanism of action combining cholinergic features including diaphoresis, altered mental status, and seizures with dopamine-related movement abnormalities including tremor, choreoathetosis, and dystonia. Management of patients poisoned by 4-AP centers around good supportive care with definitive airway management and controlling CNS hyperexcitability aggressively with gamma-aminobutyric acid agonist agents. Adjunctive use of dopamine antagonists for extrapyramidal effects after sedation is a treatment possibility. As 4-aminopyridine recently received Federal Drug Administration approval for the treatment of ambulation in patients with MS, physicians should be keenly aware of its presentation, mechanism of action, and management in overdose.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22782458      PMCID: PMC3550165          DOI: 10.1007/s13181-012-0248-9

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  61 in total

1.  Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome.

Authors:  C E Boerma; J H Rommes; R B van Leeuwen; J Bakker
Journal:  J Toxicol Clin Toxicol       Date:  1995

Review 2.  Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

3.  Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury.

Authors:  Wakana C Isoda; Jack L Segal
Journal:  Pharmacotherapy       Date:  2003-02       Impact factor: 4.705

4.  4-Aminopyridine antagonizes saxitoxin-and tetrodotoxin-induced cardiorespiratory depression.

Authors:  F C Chang; R M Bauer; B J Benton; S A Keller; B R Capacio
Journal:  Toxicon       Date:  1996-06       Impact factor: 3.033

5.  Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error.

Authors:  Eric Schwam
Journal:  J Emerg Med       Date:  2009-05-13       Impact factor: 1.484

6.  Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.

Authors:  K C Hayes; M A Katz; J G Devane; J T C Hsieh; D L Wolfe; P J Potter; A R Blight
Journal:  J Clin Pharmacol       Date:  2003-04       Impact factor: 3.126

Review 7.  Sustained-release fampridine for symptomatic treatment of multiple sclerosis.

Authors:  Anne R Korenke; Michael P Rivey; Douglas R Allington
Journal:  Ann Pharmacother       Date:  2008-09-09       Impact factor: 3.154

8.  Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial.

Authors:  D DeForge; J Nymark; E Lemaire; S Gardner; M Hunt; L Martel; D Curran; H Barbeau
Journal:  Spinal Cord       Date:  2004-12       Impact factor: 2.772

9.  Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.

Authors:  Israel Grijalva; Gabriel Guízar-Sahagún; Gilberto Castañeda-Hernández; Dolores Mino; Héctor Maldonado-Julián; Guadalupe Vidal-Cantú; Antonio Ibarra; Omar Serra; Hermelinda Salgado-Ceballos; Rita Arenas-Hernández
Journal:  Pharmacotherapy       Date:  2003-07       Impact factor: 4.705

10.  4-Aminopyridine (fampridine) effectively treats amlodipine poisoning: a case report.

Authors:  B Wilffert; R J Boskma; P H J van der Voort; D R A Uges; E N van Roon; J R B J Brouwers
Journal:  J Clin Pharm Ther       Date:  2007-12       Impact factor: 2.512

View more
  6 in total

1.  A review of 29 incidents involving 4-aminopyridine in non-target species reported to the ASPCA Animal Poison Control Center.

Authors:  Mary Kay McLean; Safdar Khan
Journal:  J Med Toxicol       Date:  2013-12

2.  High-content imaging of 3D-cultured neural stem cells on a 384-pillar plate for the assessment of cytotoxicity.

Authors:  Pranav Joshi; Soo-Yeon Kang; Kyeong-Nam Yu; Chandrasekhar Kothapalli; Moo-Yeal Lee
Journal:  Toxicol In Vitro       Date:  2020-01-07       Impact factor: 3.500

3.  Radiochemical Synthesis and Evaluation in Non-Human Primates of 3-[11C]methoxy-4-aminopyridine: A Novel PET Tracer for Imaging Potassium Channels in the CNS.

Authors:  Nicolas J Guehl; Ramesh Neelamegam; Yu-Peng Zhou; Sung-Hyun Moon; Maeva Dhaynaut; Georges El Fakhri; Marc D Normandin; Pedro Brugarolas
Journal:  ACS Chem Neurosci       Date:  2021-02-04       Impact factor: 4.418

4.  4-Aminopyridine: A Single-Dose Diagnostic Agent to Differentiate Axonal Continuity in Nerve Injuries.

Authors:  Anagha A Gurjar; Kristen M Manto; Juan A Estrada; Marc Kaufman; Dongxiao Sun; M A Hassan Talukder; John C Elfar
Journal:  Mil Med       Date:  2021-01-25       Impact factor: 1.437

5.  Central Nervous System Stimulants Limit Caffeine Transport at the Blood-Cerebrospinal Fluid Barrier.

Authors:  Kei Ikeda-Murakami; Naoto Tani; Tomoya Ikeda; Yayoi Aoki; Takaki Ishikawa
Journal:  Int J Mol Sci       Date:  2022-02-07       Impact factor: 5.923

6.  Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.

Authors:  Maria Ballesta Méndez; Vincent van Pesch; Arnaud Capron; Philippe Hantson
Journal:  Case Rep Neurol Med       Date:  2014-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.